Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
H2A clustered histone 9, pseudogene (H2AC9P), also known as HIST1H2APS3, is a member of the histone H2A gene family found in cluster 1 on human chromosome 1[5]. Unlike protein-coding histone genes, H2AC9P contains mutations and alterations in coding and flanking regions that preclude its transcription into a functional histone protein[1][3]. These alterations may include frame-shift mutations, deletions, substitutions, and loss of consensus transcriptional sequences, which make it a non-functional pseudogene rather than a true structural or regulatory protein[1][3]. Thus, H2AC9P does not contribute to nucleosome or chromatin structure and does not act as a molecular target for therapeutic intervention. Key points: - H2AC9P is classified specifically as a pseudogene and not as a protein-coding or functional histone gene[5]. - It is not considered a therapeutic target such as receptor, enzyme, transporter, or transcription factor—there is no current evidence of functional protein expression or drug interaction for this gene. - Listing this gene as a drug or diagnostic target would be incorrect based on available data[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on H2A clustered histone 9, pseudogene (H2AC9P).